Virtual coformer screening by a combined machine learning and physics-based approach. Issue 35 (21st July 2021)

• Record Type: Journal Article
• Authors: Yuan, Jiuchuang; Liu, Xuetao; Wang, Simin; Chang, Chao; Zeng, Qiao; Song, Zhengtian; Jin, Yingdi; Zeng, Qun; Sun, Guangxu; Ruan, Shigang; Greenwell, Chandler; Abramov, Yuriy A.
• Is Part Of: CrystEngComm. Volume 23:Issue 35(2021)
• Page Start: 6039
• Page End: 6044
• Publication Date: 2021-07-21
• Subjects: Crystals -- Periodicals; Crystal growth -- Periodicals; Crystallography -- Periodicals; Cristaux -- Périodiques; Cristaux -- Croissance -- Périodiques; Cristallographie -- Périodiques; 548
• DOI: 10.1039/d1ce00587a
• Languages: English
• ISSNs: 1466-8033

Abstract

Abstract : Cocrystals as a solid form technology for improving physicochemical properties have gained increasing popularity in the pharmaceutical, nutraceutical, and agrochemical industries. Abstract : Cocrystals as a solid form technology for improving physicochemical properties have gained increasing popularity in the pharmaceutical, nutraceutical, and agrochemical industries. However, the list of potential coformers contains hundreds of molecules; far more than can be routinely screened and confirmed. Cocrystal screening experiments require significant amounts of active ingredients at an early project stage, and are expensive and time-consuming. Physics-based models and machine learning (ML) models have both been used to perform virtual cocrystal screening to guide experimental screening efforts, but both have certain limitations. Here, we present a combined ML/COSMO-RS fast virtual cocrystal screening method that proves to be significantly better than the sum of its parts in application to internal and external validation sets. To achieve that, we have defined the optimal threshold values of ML cocrystallization probability and COSMO-RS excess enthalpy of drug/coformer mixing for the combined coformer ranking. An approach to determine an applicability domain (AD) of the ML model has been implemented. The speed and accuracy of the new combined model allow it to be a good alternative to the physics-based CSP-based approach to support pharmaceutical projects with tight timeline and budget constraints.